We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Novel Immunotherapy Approach Shrinks or Eliminates Advanced Tumors

By LabMedica International staff writers
Posted on 03 Nov 2016
A novel four-component approach to anti-cancer immunotherapy overcame the complex network of immunosuppressive pathways present in advanced tumors and caused shrinkage of several types of tumors in different mouse models.

Up to now attempts to treat tumors with immunotherapy have had only limited success probably due in part to the complex network of immunosuppressive pathways present in advanced tumors, which are unlikely to be overcome by intervention at a single signaling checkpoint.

To deal with these multiple pathways, investigators at the Massachusetts Institute of Technology (Cambridge, USA) developed a combination immunotherapy approach that recruited a variety of innate and adaptive immune cells. More...
The treatment comprised four parts: an antibody targeted to the tumor, a vaccine targeted to the tumor; the cytokine interleukin-2 (IL-2), and a molecule that blocked the programmed cell death 1 (PD1) protein, a receptor found on T-cells. Each component had a critical role to perform. The antibodies stimulated the recruitment of additional immune cells that helped to activate T-cells; the vaccine stimulated proliferation of T- cells to attack the tumor; IL-2 prompted the T-cell population to expand quickly; and the anti-PD1 molecule extended T-cell activity.

The investigators tested this combination treatment in mice that had been implanted with three different types of tumors: melanoma, lymphoma, and breast cancer. They reported in the October 24, 2016, online edition of the journal Nature Medicine that about 75% of the well-established tumors in all strains of experimental mice were completely eliminated. Furthermore, six months later, the immune systems of these mice retained the ability to completely clear freshly injected tumor cells.

"We have shown that with the right combination of signals, the endogenous immune system can routinely overcome large immunosuppressive tumors, which was an unanswered question," said senior author Dr. Darrell Irvine, professor of biological engineering and of materials science and engineering at the Massachusetts Institute of Technology. "We had this really good lymph-node-targeting vaccine that will drive very strong adaptive immunity, and they had this combination that was recruiting innate immunity very efficiently. We wondered if we could bring these two together and try to generate a more integrated immune response that would bring together all arms of the immune system against the tumor."

Related Links:
Massachusetts Institute of Technology


New
Gold Member
Latex Test
SLE-Latex Test
Serological Pipet Controller
PIPETBOY GENIUS
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
New
PlGF Test
Quidel Triage PlGF Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: How the predictive test works (Photo courtesy of QMUL)

World’s First Clinical Test Predicts Best Rheumatoid Arthritis Treatment

Rheumatoid arthritis (RA) is a chronic condition affecting 1 in 100 people in the UK today, causing the immune system to attack its joints. Unlike osteoarthritis, which is caused by wear and tear, RA can... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.